NCT02952625

Brief Summary

This is a pilot non-intervention study that aims to introduce PET/MRI, a state of the art new imaging technique, into the radiotherapy treatment pathway of patients with head and neck cancer. Ultimately the investigators aim to establish appropriate scanning and image registration protocols, to allow progression to a randomized trial of adaptive radiotherapy dose escalation. The latter is thought to potentially improve outcomes in this group. Ten patients with squamous cell carcinoma (SCC) of the oropharynx, hypopharynx and larynx, planned for radical treatment with radiotherapy (+/-chemotherapy), will be recruited. Study participants will have two PET/MRI scans, with the radiotherapy immobilization devices in situ. The first will be done prior to the start of radiotherapy, the second half way through treatment. Image quality will be assessed by comparing to standard diagnostic scans and different registration methods will be compared to establish the best way of incorporating PET/MR image data into the radiotherapy planning system. Patient tolerability and workflow considerations will also be qualitatively assessed. Furthermore, a planning study will be conducted to establish relevant treatment protocols for a subsequent dose escalation trial. PET/MRI is an exciting new technology with a lot of potential in the context of adaptive radiotherapy dose escalation. Within this pilot study the investigators aim to address the technical challenges of using it in this context prior to proceeding to a randomized trial.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
8

participants targeted

Target at below P25 for not_applicable head-and-neck-cancer

Timeline
Completed

Started Apr 2016

Shorter than P25 for not_applicable head-and-neck-cancer

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2016

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

October 25, 2016

Completed
8 days until next milestone

First Posted

Study publicly available on registry

November 2, 2016

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2017

Completed
Last Updated

August 29, 2019

Status Verified

August 1, 2019

Enrollment Period

1.3 years

First QC Date

October 25, 2016

Last Update Submit

August 27, 2019

Conditions

Keywords

PET/MRI

Outcome Measures

Primary Outcomes (2)

  • Number of scans where image quality is sufficient to characterise the primary tumour, assessed qualitatively by an experienced radiologist and oncologist

    6 months following study completion

  • Proportion of patients that tolerated the full scanning protocol, assessed by tailored patient questionnaire

    6 months following study completion

Study Arms (1)

Single arm imaging study

OTHER

Single arm study: all patients have 2 PET/MR scans in the radiotherapy treatment position

Other: Imaging

Interventions

ImagingOTHER

Single arm Imaging (PET/MR) study

Single arm imaging study

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Written, voluntary, informed consent
  • Age ≥ 18
  • Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2
  • Life expectancy \> 12 months
  • Histologically proven SCC of the oropharynx, hypopharynx and larynx
  • Radical radiotherapy +/- chemotherapy indicated as the primary treatment modality
  • Visible disease (\>1cm) at the primary site on any imaging modality performed within 4 weeks of starting radiotherapy treatment
  • Staging PET/CT and diagnostic MRI of the head and neck images need to be available for comparison.
  • Adequate organ function and absence of other major concurrent illness, allowing the patient to tolerate scanning regime

You may not qualify if:

  • Inability to provide informed consent
  • Impaired renal function (serum creatinine of \> 200)
  • Severely impaired liver function
  • Patients with allergies or contra-indications to the radio-tracer and/or contrast agent used in the study
  • Severe claustrophobia or inability to tolerate PET or MRI scans
  • General contra-indications to MRI, as defined in MRI safety departmental protocols
  • Serious inter-current conditions or other non-malignant illnesses that are uncontrolled or whose control may be affected by participation in this study
  • Any patient who has urinary or faecal incontinence
  • ECOG Performance Status ≥ 3
  • Pregnant or breastfeeding women

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Guy's & St Thomas' NHS Foundation Trust

London, United Kingdom

Location

MeSH Terms

Conditions

Head and Neck Neoplasms

Interventions

X-Rays

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasms

Intervention Hierarchy (Ancestors)

Electromagnetic RadiationElectromagnetic PhenomenaMagnetic PhenomenaPhysical PhenomenaRadiationRadiation, Ionizing

Study Officials

  • Teresa Guerrero Urbano

    Guy's & St Thomas' NHS Foundation Trust, London, UK

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 25, 2016

First Posted

November 2, 2016

Study Start

April 1, 2016

Primary Completion

August 1, 2017

Study Completion

August 1, 2017

Last Updated

August 29, 2019

Record last verified: 2019-08

Data Sharing

IPD Sharing
Will not share

Locations